

Mini biographies for selected speakers and panellists

Sir John Bell (Alberta & Magdalen 1975)

Professor Sir John Bell FRS is Regius Professor of Medicine at Oxford University and past President of the Academy of Medical Sciences. Sir John undertook his medical training in Oxford as a Rhodes Scholar and at Stanford University, returning to the UK in 1987. He became Nuffield Professor of Clinical Medicine in Oxford in 1992. His research interests are in the area of immunology and genetics, where he has contributed to the understanding of immune activation in a range of autoimmune diseases. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world's leading centres for complex trait common disease genetics. Sir John was responsible for the working party that produced the highly influential Academy of Medical Sciences "Strengthening Clinical Research" report that highlighted the need for the UK to focus some of its attention on developing expertise in translational research. In January 2007, he became the first Chairman of the Office for the Strategic Coordination of Health Research. He is Chairman of the Bill and Melinda Gates Foundation Global Health Program Advisory Committee and contributes to numerous other international advisory boards. He has been involved in founding four biotechnology companies and is on the Board of Roche AG. Sir John is an Emeritus Trustee of the Rhodes Trust.

Bonnie Blanchfield

Bonnie writes: 'My current professional positions are: Senior Scientist, Clinical Innovation Center, Brigham and Women's Hospital and Director of Program Evaluation, Brigham and Women's Physician Organization. I function now in both a research (health care costs and policy) role and in a hospital operations role (value and innovation). My path to these roles started by working in public accounting and corporate management, followed by a doctorate degree at Harvard's School of Public Health and subsequent consulting, research and management roles for the past 25 years. My research focus includes understanding health care costs and how to measure and report value.'

Chas Bountra

Chas is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes. Prior to coming back to Oxford, Chas was Vice President and Head of Biology at GlaxoSmithKline. His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively; ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases; iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimer's Disease, and creating a "BioEscalator" for the rapid translation of SGC science; and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies to create a new, more efficient ecosystem for pioneer drug discovery.

Rhodes Biomedicine Weekend

Gerald Chan

Dr. Gerald Chan is a director of publicly listed Hang Lung Group Limited, a Hong Kong-based property holding company. He serves on the boards of several biotechnology companies in North America and Europe including Stealth Peptides, Advanced Cell Diagnostics, Matrivax, Vaccine Technologies Inc., and Oxyrane. He is a member of the Global Advisory Council of the International Society for Stem Cell Research, the International Board of Governors of the New York Academy of Sciences, the Board of Trustees of Fudan University in Shanghai, the Global Advisory Council of Harvard University, and chairs the Board of Overseers of the Morningside College of the Chinese University of Hong Kong. In 1987, Dr. Chan co-founded Morningside, a diversified investment group engaged in private equity and venture capital investments in North America, Asia and Europe. Morningside has been an active investor in China since 1992. Dr. Chan received his BS and MS degrees in Engineering from UCLA, a Master of Science degree in Medical Radiological Physics, and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training in pathology at the Harvard Medical School and the Dana-Farber Cancer Institute.

Fred Cohen (Florida & Wolfson 1978)

Dr. Fred Cohen is a Partner at TPG and co-founder of TPG Biotechnology, a life science focused investment effort. For the last 15 years, Dr. Cohen has been responsible for co-leading the Biotechnology investment effort at TPG. The Biotechnology team has invested in over 50 companies covering areas of Drug Discovery and Development, Personalized Medicine, Allied Pharmaceutical Services, Industrial Biotechnology and Medical Technology. The group was formed in 2002 and is investing its fourth fund. Currently, TPG Biotechnology manages over \$1 billion in assets and is an integral part of the firm's larger healthcare efforts. From 1980 through 2014, Dr. Cohen was at UCSF where he held various clinical responsibilities as an Internist for hospitalized patients, a consulting Endocrinologist, and as the Chief of the Division of Endocrinology and Metabolism.

Terrence J. Donnelly, C.M., O.ONT., LL.D. (HON.)

Terrence Donnelly was born in London, Ontario, and graduated from the University of Western Ontario with an Honours degree in Business Administration in 1957. In 1960 he graduated from Osgoode Hall Law School in Toronto, a medallist in his class, and was called to the Bar of Ontario in 1962. He was awarded the Order of Ontario, 2001 in recognition of his interest and support for projects in healthcare in the province; he also received an Honorary Doctor of Law in 2005 from the University of Toronto in recognition of his commitment and support for research in healthcare and life sciences. In 2014, he was awarded the Order of Canada for his philanthropic contributions to health care and medical research.

Antonio M. Gotto, Jr., MD, DPhil (Tennessee & Worcester 1957)

Dr. Antonio Gotto is the Dean Emeritus of Weill Cornell Medical College in New York, NY, where he is also the Provost for Medical Affairs Emeritus of Cornell University. Dr. Gotto previously served as the Stephen and Suzanne Weiss Dean, Lewis Thomas University Professor, and Co-Chairman of the Board of Overseers at Weill Cornell. He is also on the boards of Aegerion Pharmaceuticals, Arisaph Pharmaceuticals, and Esperion Therapeutics.

Rhodes Biomedicine Weekend

Sir Bruce Keogh

Professor Sir Bruce Keogh is NHS England's Medical Director and professional lead for NHS doctors. He is responsible for promoting clinical leadership, quality and innovation.

Formerly, Sir Bruce had a distinguished career in surgery. He was Director of Surgery at the Heart Hospital and Professor of Cardiac Surgery at UCL. He has been President of the Society for Cardiothoracic Surgery in Great Britain and Ireland, Secretary-General of the European Association for Cardio-Thoracic Surgery, International Director of the US Society of Thoracic Surgeons, and President of the Cardiothoracic Section of the Royal Society of Medicine. He has served as a Commissioner on the Commission for Health Improvement (CHI) and the Healthcare Commission. He was knighted for services to medicine in 2003.

Andrew Lynk (Maritimes & Balliol 1983)

Andrew Lynk is a consultant paediatrician and child advocate who practices in Cape Breton, Nova Scotia. After receiving an MSc in Clinical Tropical Medicine as a Rhodes Scholar, he worked in Ethiopian refugee camps during the great famine of 1985-6. He has extensive experience in governmental advocacy campaigns with tobacco control, adolescent health and injury prevention. More recently, he has served as President of the Canadian Paediatric Society, Medical Director of Cancer Care and VP Medicine with the Cape Breton Health Authority, with ongoing interests in patient safety, medical education, global child health and leadership. Despite a successful Oxford Blues Hockey career, he was completely overlooked by the Maple Leafs.

Carl Marci (Pennsylvania & St Catherine's 1991)

Dr. Carl D. Marci is Chief Neuroscientist of Nielsen Consumer Neuroscience. He is also on faculty at Harvard Medical School and is the former Director of Social Neuroscience at the Massachusetts General Hospital and past Visiting Lecturer at the Massachusetts Institute of Technology Program in Media Arts & Sciences. Dr. Marci received his MA in Psychology and Philosophy at Oxford University as a Rhodes Scholar and then completed his M.D. with honors at Harvard Medical School. He has extensive training in the use of biometrics and the neuroscience of emotion through two National Institutes of Health fellowships. Co-founder of Innerscope Research in 2006, Dr. Marci was CEO from 2008 to 2013 and the company was acquired by Nielsen in 2015. Dr. Marci and the company's innovative research has been featured in the New York Times, Wall Street Journal, Advertising Age, Media Post, Psychology Today, Wired Magazine, Fast Company and the International Herald Tribune, and Dr. Marci has been interviewed by CNN, MSNBC and Fox News. He has presented at the Interdisciplinary Symposium on Decision Neuroscience, the Advertising Research Foundation, the Association of National Advertisers, the Cable & Telecommunications Association for Marketing, the World Advertising Research Conference, ESOMAR and the Festival of Media Global Event. Dr. Marci was also a guest editor of Media Magazine and the International Journal of Advertising Special Issue on Advertising and the Brain. He has published numerous articles in peer-reviewed science journals, gives lectures nationally and internationally, and is a pioneer in the new fields of social and consumer neuroscience.

Rhodes Biomedicine Weekend

Gregg Meyer (New York & Oriel 1986)

Dr. Gregg S. Meyer is an internationally known leader in health care quality and safety. As the Chief Clinical Officer of Partners HealthCare System in Boston, MA, he is responsible for overall direction, operations, and management of system aspects of healthcare delivery throughout the not-for-profit consortium. He is also an associate professor of medicine at The Dartmouth Institute of Health Policy and Clinical Practice, and he previously served as Chief Clinical Officer and Executive Vice President for Population Health at Dartmouth-Hitchcock Medical Center.

Prior to joining Dartmouth-Hitchcock, Dr. Meyer served as senior vice president for the Edward P. Lawrence Center for Quality and Safety at the Massachusetts General Hospital (MGH) and Massachusetts General Physicians Organization (MGPO). He led the efforts of the MGH/MGPO in quality and safety and the redesign efforts at Mass General, which aimed to improve both the quality and efficiency of care for common clinical conditions. As Medical Director of the MGPO, the largest physician group practice in New England, Dr. Meyer developed novel approaches to payment for performance and led a team that created a care management program for vulnerable Medicare beneficiaries which has been cited by the Congressional Budget Office as one of the few CMS Demonstration programs that measurably improved quality while generating real savings to the healthcare system.

Susanna Mierau (Kansas & Balliol 2000)

Susanna writes: 'As a neuroscientist-neurologist, my research focuses on how sensory experience shapes the developing brain and how these processes are disturbed in autism and related neurodevelopmental disorders. After completing my D.Phil. in Neuroscience at Oxford, I attended medical school, neurology residency, and clinical fellowship at Harvard. After completing my training, I devoted 80-90%-time to basic science research in autism and 10-20%-time to caring for children and adults with autism as a staff neurologist at the Massachusetts General Hospital Lurie Center for Autism and teaching medical and neuroscience graduate students as a faculty member at Harvard. In 2015, I began full-time research and teaching as a research fellow in the Physiology, Development, and Neuroscience Department at the University of Cambridge.'

Errol R. Norwitz, M.D., Ph.D. (South Africa-at-Large & University 1988)

Dr. Errol Norwitz is the Louis E. Phaneuf Professor and Chair of Obstetrics & Gynecology at Tufts Medical Center and Tufts University School of Medicine in Boston. He completed his medical training at the University of Cape Town (South Africa), his Ph.D. at Oxford University (England) on a Rhodes Scholarship, and his Ob/Gyn Residency and Maternal-Fetal Medicine Fellowship at Harvard University in Boston. From 2003 through 2010, he was Professor of Obstetrics, Gynecology & Reproductive Sciences at Yale University School of Medicine as well as Director of the Division of Maternal-Fetal Medicine, Director of the Maternal-Fetal Medicine Fellowship Program, and Director of the Obstetrics & Gynecology Residency Program at Yale-New Haven Hospital in New Haven, CT. Most recently, he is a Founding Investigator of the Mother Infant Research Institute at Tufts Medical Center in Boston. He is the author of nine textbooks, 80 book chapters, and more than 250 original research articles. His research has been supported by NIH/NICHD and March of Dimes. His areas of research interest include the genetics of adverse pregnancy outcome and the molecular regulation of parturition, both at term and preterm.